These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4833918)

  • 1. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
    Hiramoto RN; Ghanta VK
    Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Hiramoto R; Ghanta V; Durant JR
    Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantable mouse plasma cell tumors in experimental chemotherapy.
    Teller MN; Abraham D; Bowie M; Carbone PP
    J Natl Cancer Inst; 1969 Jul; 43(1):123-31. PubMed ID: 5816022
    [No Abstract]   [Full Text] [Related]  

  • 4. Imuran-induced regression of plasma cell tumor MOPC-315.
    Schlossberg M; Hollander VP
    Cancer Res; 1973 Aug; 33(8):1953-6. PubMed ID: 4720804
    [No Abstract]   [Full Text] [Related]  

  • 5. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An experimental model for evaluation of factors in tumor escape from immunological attack.
    Yutoku M; Fuji H; Grossberg AL; Pressman D
    Cancer Res; 1975 Mar; 35(3):734-9. PubMed ID: 1116132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.
    Frondoza CG; Trivedi SM; Humphrey RL
    Cancer Treat Rep; 1982 Jul; 66(7):1535-44. PubMed ID: 7093969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.
    Teller MN; Bowie M; Mountain IM; Stock CC
    J Natl Cancer Inst; 1974 Mar; 52(3):667-71. PubMed ID: 4857022
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of host immunity with 5-fluorouracil-initiated cure of plasmacytoma LPC-1 in BALB/c mice.
    Teller MN; Faanes RB
    Cancer Res; 1980 Aug; 40(8 Pt 1):2790-5. PubMed ID: 6966969
    [No Abstract]   [Full Text] [Related]  

  • 14. Quantitation of total-body tumor cells (MOPC 104E). I. Subcutaneous tumor model.
    Ghanta VK; Hiramoto RN
    J Natl Cancer Inst; 1974 Apr; 52(4):1199-202. PubMed ID: 4826588
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo-in vitro tumor systems: new models for studing the response of tumours to therapy.
    Rockwell S
    Lab Anim Sci; 1977 Oct; 27(5 Pt 2):831-51. PubMed ID: 338981
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of intraperitoneal pristane on established immunity to the adj-PC-5 plasmacytoma.
    Potter M; Walters JL
    J Natl Cancer Inst; 1973 Sep; 51(3):875-81. PubMed ID: 4743559
    [No Abstract]   [Full Text] [Related]  

  • 17. Stem-cell survival and tumor control in the Lewis lung carcinoma.
    Steel GG; Adams K
    Cancer Res; 1975 Jun; 35(6):1530-5. PubMed ID: 1169108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexamethylmelamine-induced regression of human lung tumors growing in immune deprived mice.
    Mitchley BC; Clarke SA; Connors TA; Neville AM
    Cancer Res; 1975 Apr; 35(4):1099-102. PubMed ID: 1116144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered sensitivity of a hamster plasmacytoma to cytosine arabinoside (NSC-63878).
    Griswold DP; Simpson-Herren L; Schabel FM
    Cancer Chemother Rep; 1970 Oct; 54(5):337-46. PubMed ID: 5514623
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of low-dose melphalan treatment against a nonimmunogenic primary induced mouse plasmacytoma.
    Ophir R; Pick AI; Ben-Efraim S
    Anticancer Res; 1987; 7(1):91-6. PubMed ID: 3566188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.